PBA
ISEE

Paradigm Biocapital Advisors’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-910,416
Closed -$15.3M – 29
2022
Q1 		$15.3M Buy
910,416
+94,835
+12% +$1.4M 4.05% 8
2021
Q4 		$13.6M Buy
+815,581
New +$13.4M 3.89% 12

Other funds holding ISEE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Paradigm Biocapital Advisors's ISEE Position: Q2 2022 in Review

Paradigm Biocapital Advisors sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q2 2022, closing a stake of 910,416 shares — an estimated $15.3M sold.

Paradigm Biocapital Advisors first reported a position in ISEE in Q4 2021 and held it in 2 quarters. The position peaked at $15.3M in Q1 2022. 184 funds tracked by Wall St. Rank hold ISEE as of Q2 2022.

  • Paradigm Biocapital Advisors reported no remaining IVERIC bio, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 910,416 IVERIC bio, Inc. Common Stock shares in Q2 2022, an estimated $15.3M.
  • Paradigm Biocapital Advisors first reported a position in IVERIC bio, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's IVERIC bio, Inc. Common Stock position peaked at $15.3M in Q1 2022.
  • 184 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q2 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.